Use of the ZMIZ1 marker in directing treatment and predicting survival in cancer
US10174384B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2016 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Mar 16, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions for treating cancer and predicting patient survival. In one embodiment, a method comprises (a) obtaining a biological sample from the patient; and (b) detecting hypermethylation of ZMIZ1 using primers that specifically bind to CpG island 139 at the alternative promoter of the ZMIZ1 gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.